Who is Xoma Corporation?
Touch device users, explore by touch or with swipe gestures. XOMA Corporation is a biotechnology royalty aggregator playing a unique role in helping biotech companies to improve human health.
Can XOMA (XOMA) beat earnings expectations?
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space.
Who is Mark Lampert and what did he do for XOMA?
Mark Lampert is an American investor who founded BVF Partners Ltd. […] Xoma (XOMA) delivered earnings and revenue surprises of -466.67% and -85.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
When will XOMA pay its first dividend?
When did XOMA close?
On April 15, 2021, the Company paid its first dividend on Series A Cumulative Perpetual Preferred (Nasdaq: XOMAP) in the amount of $0.71875 per share. The Company continues to believe its current cash position will be sufficient to fund XOMA’s operations for multiple years.
What is the net loss for XOMA in 2021?
On April 12, 2021, XOMA announced the closing of its Depositary Shares Offering and the exercise of the underwriters’ option, which resulted in approximately $38.0 million after deducting underwriting discounts and commissions, but before expenses.
How much interest is XOMA 2021?
Net loss for the first quarter of 2021 was $7.4 million, compared to net loss of $4.8 million for the first quarter of 2020. On March 31, 2021, XOMA had cash of $67.8 million. The Company ended December 31, 2020, with cash of $84.2 million.
Is XOMA a big mover?
In the first quarter of 2021, XOMA recorded $0.3 million in total interest expense, as compared to $0.5 million in the corresponding period of 2020, both of which reflect the Company’s outstanding loan balances with Silicon Valley Bank and Novartis.
What is XOMA Corp?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What is market cap?
XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics. Its proprietary product candidates are X358, X213, X129, and Gevokizumab. The business operations of the company function through the United States, Europe, and the Asia Pacific.
Does market cap include convertible securities?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.